the Relationship Between Allergic Rhinitis and the Risk of Symptom in Patients With Mild COVID-19

NCT05753241 | Completed DMC

• 1 other identifier: CDUTCM20230301
• Study Type: observational
• Target: 1,100
• Locations: 1 country
• Sites: 1

Brief Summary

At present, most studies mainly focussed on severe patients, and there was no comparison of symptom differences between AR patients and healthy people with mild infection to evaluate the symptoms of AR patients during infection and to provide preventive treatment in advance. So this experiment was designed.

Conditions

COVID-19; Allergic Rhinitis

Keywords

allergic rhinit; sublingual immunotherapy; the symptoms after COVID-19 infection; Odds ratio

Outcome Measures

Primary Outcomes (2)

• post-infection symptoms（pharyngeal symptoms；Systemic symptoms； Gastrointestinal symptoms；Olfactory and gustatory dysfunction；Severe symptoms）

  pharyngeal symptoms: dry throat, itchy throat, sore throat, cough, expectoration; Systemic symptoms: fever, headache, fatigue, cold limbs; Gastrointestinal symptoms: diarrhea, constipation; Olfactory and gustatory dysfunction: hypoosmia, hypogustia; Severe symptoms: chest tightness, pant, palpitation, convulsion, coma.

  The first day after COVID-19 infection

• hospitalization rate

  The probability of needing hospital treatment after infection

  The first day after COVID-19 infection

Study Arms (3)

healthy group (HG)

Participants were grouped according to their basic conditions without any intervention

Other: no intervention

allergen immunotherapy group (AIT)

Participants were grouped according to their basic conditions without any intervention

Other: no intervention

allergic rhinitis group (ARG)

Participants were grouped according to their basic conditions without any intervention

Other: no intervention

Interventions

no intervention OTHER

It's only observational study. No interventions.

allergen immunotherapy group (AIT); allergic rhinitis group (ARG); healthy group (HG)

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study period will include all patients attending the ENT outpatient clinic (AR and NO-AR) from December 1, 2022 to December 1, 2023

You may qualify if:

• all participants completed at least one antigen or nucleic acid test and the results were positive.
• the diagnoses of AR met the international diagnostic standards for AR. The participants had obvious clinical symptoms and the allergen test was positive.

You may not qualify if:

• suspected new infected person with symptoms（ no antigen or nucleic acid test and the results were nagetive ）
• Participants requiring ICU admission after COVID-19 infection-

Sponsors & Collaborators

• qinxiu zhang: lead

Study Sites (1)

Hospital of Chengdu University of Traditional Chinese Medicine

Chengdu, 615100, China

Location

Related Publications (1)

• Zhang S, Liu C, Liu Q, He X, Fu Q, Chen X, Jin X, Chen Z, Yang X, Zhang Q, Li X. The relationship between sublingual immunotherapy for allergic rhinitis and the risk of symptoms in patients with COVID-19 infection. Hum Vaccin Immunother. 2023 Aug 1;19(2):2236538. doi: 10.1080/21645515.2023.2236538.

  PMID: 37530139 RESULT

Related Links

• Related Info

MeSH Terms

Conditions

COVID-19; Rhinitis, Allergic

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Rhinitis; Nose Diseases; Respiratory Hypersensitivity; Otorhinolaryngologic Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• qinxiu zhang, Dr.

  Chengdu University of Traditional Chinese Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Month
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor, School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine

Study Record Dates

• First Submitted: March 1, 2023
• First Posted: March 3, 2023
• Study Start: November 10, 2022
• Primary Completion: June 20, 2023
• Study Completion: June 22, 2023
• Last Updated: March 1, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)